Literature DB >> 12730744

The effect of DXA scanning on clinical decision making by general practitioners: a randomized, prospective trial of direct access versus referral to a hospital consultant.

V Dhillon1, J Creiger, J Hannan, N Hurst, G Nuki.   

Abstract

The objective of the study was to assess the impact of direct access DXA scanning (DADS) upon GPs' management decisions in patients considered to be at risk of osteoporosis. It was designed as a randomized, prospective, parallel group trial, set within the primary care environment and a university teaching hospital. The participants were 330 patients aged 31 to 89 years from 18 general practices in Edinburgh. Patients were randomized to either DADS or to the current system of specialist referral (controls). The primary outcome measure was frequency of change of management after DXA scanning. Secondary outcome measures were: change in health status, adherence to therapy, clinical events and resource use at one-year follow-up. The primary outcome was that 60% each of DADS patients (98/165) and controls (99/165) had changes in management following DXA scanning. In 30% of patients (12/41) in whom GPs had proposed changing management even in the absence of a scan, different therapy was chosen after the scan (no difference between DADS and control groups). There was an improvement in health utility (p =0.014 for both groups combined), differing slightly between the two groups even after age correction (p =0.014). 68% of the DADS group and 70% of controls were adherent to therapy after one year. In terms of clinical events, at one year there was one major adverse event (control group patient), 5 new fractures in the DADS group and 3 in controls - there were no hip fractures in this study. With regard to resource use, there were 24 referrals to hospital specialist after DXA scanning among the DADS group, vs 12 among controls (p < 0.05). The total number of visits to health professionals was 525 in DADS and 585 in controls (p=ns); mean waiting time from randomization to receipt of report/clinic letter was 4 weeks for DADS vs 13 weeks for controls( p < 0.0001). In conclusion, DXA scanning resulted in management change in at least 60% of cases. Direct access does not result in a clinical outcome significantly different from a consultant led service, and is more economically efficient than the current model of hospital referral.

Entities:  

Mesh:

Year:  2003        PMID: 12730744     DOI: 10.1007/s00198-002-1371-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  11 in total

1.  Bone densitometry is not a good predictor of hip fracture.

Authors:  T J Wilkin; D Devendra
Journal:  BMJ       Date:  2001-10-06

2.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

Review 3.  Consensus development conference: prophylaxis and treatment of osteoporosis.

Authors: 
Journal:  Am J Med       Date:  1991-01       Impact factor: 4.965

4.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

Authors:  J Brazier; N Jones; P Kind
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

5.  Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations.

Authors:  J M Grimshaw; I T Russell
Journal:  Lancet       Date:  1993-11-27       Impact factor: 79.321

Review 6.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

7.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

8.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

Review 9.  Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities.

Authors:  E Seeman
Journal:  Am J Med       Date:  1993-11-30       Impact factor: 4.965

10.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; M C Nevitt; W S Browner; K Stone; K M Fox; K E Ensrud; J Cauley; D Black; T M Vogt
Journal:  N Engl J Med       Date:  1995-03-23       Impact factor: 91.245

View more
  3 in total

Review 1.  Referral interventions from primary to specialist care: a systematic review of international evidence.

Authors:  Lindsay Blank; Susan Baxter; Helen Buckley Woods; Elizabeth Goyder; Andrew Lee; Nick Payne; Melanie Rimmer
Journal:  Br J Gen Pract       Date:  2014-12       Impact factor: 5.386

2.  Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fracture.

Authors:  Veena Dhillon; Nigel Hurst; Jim Hannan; George Nuki
Journal:  Osteoporos Int       Date:  2004-07-28       Impact factor: 4.507

Review 3.  Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials.

Authors:  Monika Kastner; Sharon E Straus
Journal:  J Gen Intern Med       Date:  2008-10-04       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.